Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T cell receptor alpha constant (TRAC), preventing CAR-T ... is a clinical-stage U.S. biotechnology company developing the ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced the dosing of the first ...

MDS is a heterogeneous group of myeloid neoplasms originating from hematopoietic stem cells, with a high risk of transformation into acute myeloid leukemia (AML). Natural Killer (NK) cells, crucial ...

The North Kingstown Skippers girls basketball team won the 2025 Rhode Island Interscholastic League Girls Basketball Division I Championship against the Ponaganset Chieftains. The Skippers ...

Morningstar brands and products Company Portfolio ...

"authentically local news that listens to you" ...

anti-CD7 CAR-T cell therapy for pediatric and adult patients with relapsed or refractory (R/R) T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma (T-ALL/LBL). "The data we have ...